

## Remarks

The Applicants address the Examiner's remarks in the order presented. Amendments to the specification require the submission of a new sequence listing that is included with this response. Accordingly, a statement pursuant to 37 C.F.R. 1.821 (f) stating that the content of the sequence listing information recorded in computer readable form is identical to the written sequence listing and includes no new matter is included.

### Objections to the Specification

The Examiner has objected to the specification because description of the Figures 3 and 4 do not contain sequence identifiers. The specification has been amended to include SEQ ID NOs in the description of Figures 3 and 4. Further, the Examiner has noted sequences in the text of the specification with SEQ ID NOs (page 77 and 78) that are not listed in the sequence listing. These sequences have been added to the sequence listing submitted with this amendment and is to replace all prior sequence listings. Sequences found on page 25 and 79 were assigned SEQ ID NOs, added to the sequence listing, and the appropriate SEQ ID NOs were amended in the specification. Applicant also amended sequence identifiers to page 12 of the specification. Accordingly, withdrawal of the objections to the specification is respectfully requested.

### Rejection under 35 USC §101

Claims 44-46 are rejected under 35 USC §101 for allegedly not asserting a specific, substantial and credible utility. Applicant has taken the Examiner's suggestion to amend the description of Figures 6 and 7 to make the record clear that SEQ ID NO: 2 is the receptor that was expressed in the cells that demonstrated calcium mobilization and the cAMP response. Support for this amendment is found throughout the specification, for example, on pages 82-83 of the instant application. Withdrawal of the rejection is respectfully requested.

### Rejection under 35 USC §112 First Paragraph

Claims 44-46 were rejected by the Examiner under 35 USC §112 First Paragraph allegedly failing to teach how to use the instant invention because one skilled in the art

would not know how to use the instant invention if the claimed invention lacked utility. The amendment to the specification addressing the utility rejection under 35 USC §101 has rendered the 35 USC §112 First Paragraph rejection moot. Thus, reconsideration and withdrawal of this rejection is requested.

Rejection under 35 USC §112 Second Paragraph

Claims 44-46 were rejected under 35 USC §112 Second Paragraph as being incomplete for omitting essential steps. Applicants thank the Examiner for his suggestions on alternative claim language and have amended the claims. No new matter has been added. Accordingly, withdrawal of this rejection is respectfully requested.

Title of the Invention

The Examiner has requested a new title to indicate the invention to which the claims are directed. Applicants have amended the title to be descriptive of the pending claims.

Applicants respectfully submit that the application is now in condition for allowance and request notice thereof. If there are any issues that can be resolved by a telephone conference or an Examiner's amendment, the Examiner is invited to call the undersigned attorney at (908) 231-4757.

Respectfully submitted,

  
Ann Marie Szczepanik, Reg. No. 52, 267  
Attorney/Agent for Applicant

sanofi-aventis US LLC  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-4757  
Telefax (908) 231-2626

Docket No. USAV2003/0073 US NP